Neuropeptide S vs Omentin-1
Head-to-head comparison of Neuropeptide S (Neuropeptide S) and Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Neuropeptide S | Omentin-1 |
|---|---|---|
| Category | Cognitive Enhancement | Diabetes & Metabolic |
| Full Name | Neuropeptide S | Omentin-1 (Intelectin-1, ITLN1) |
| Molecular Weight | 2203 Da | ~35 kDa |
| Half-Life | Minutes to <1 hour | hours |
| Amino Acids | 20 | 313 |
| Typical Dose | Research-only; no validated human dose | No approved human dose; research use only |
| Route | Intracerebroventricular/Intranasal | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 28 | 82 |
| Research Status | Pre-clinical | Pre-clinical |
Neuropeptide S Benefits
- ✓anxiolysis
- ✓stress resilience
- ✓attention support
- ✓arousal modulation
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Neuropeptide S Dosing
0.1-1 nmol i.c.v. in animal studies|intranasal research-only exploration|no established human protocol
Omentin-1 Dosing
not established|not established
Neuropeptide S Side Effects
- ⚠sleep disruption
- ⚠headache
- ⚠jitteriness
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
Neuropeptide S
Animal studies suggest NPS can reduce anxiety-like behavior while altering wakefulness and alertness through the NPS receptor system. Human cognitive data are very limited, and it has no approved clinical indication.
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.